Most frequently, cancer-associated suppression of PP2A occurs by non-genomic alterations [24], such as increased expression of oncogenic cellular PP2A inhibitors, which are thought to inhibit the activity of specific tumor-suppressive PP2A holoenzymes [25]. Here, PTPA is linked to neoplasm.